文献速递细菌感染、耐药与抗菌药物真菌感染

接受依鲁替尼治疗淋巴系统肿瘤患者的严重感染

Serious Infections in Patients Receiving Ibrutinib for Treatment of Lymphoid Cancer.
PubMed 文献 · Clin Infect Dis · 2018-01-01

该研究回顾了2012年1月1日至2016年12月31日五年间在纪念斯隆凯特琳癌症中心接受依鲁替尼治疗的378例淋巴系统肿瘤患者的电子病历,发现43例(11.4%)发生严重感染,主要发生在治疗第一年,其中侵袭性细菌感染23例(53.5%),侵袭性真菌感染16例(37.2%),感染导致6例(14%)死亡。

要点

  • 378例接受依鲁替尼治疗的淋巴系统肿瘤患者中,43例(11.4%)发生严重感染,主要见于治疗第一年。
  • 严重感染中侵袭性细菌感染23例(53.5%),侵袭性真菌感染16例(37.2%)。
  • 侵袭性真菌感染患者中62.5%缺乏经典临床危险因素(中性粒细胞减少、淋巴细胞减少、接受糖皮质激素)。

核心结论

  • 接受依鲁替尼治疗的淋巴系统肿瘤患者存在严重感染风险,包括侵袭性真菌感染。

研究设计与样本

  • 回顾性研究,纳入纪念斯隆凯特琳癌症中心2012年1月1日至2016年12月31日五年期间接受依鲁替尼治疗的378例淋巴系统肿瘤患者,通过复习微生物学、临床实验室和影像学资料确定严重感染,采用单因素和多因素分析确定感染危险因素。

主要发现

  • 最常见的 underlying 癌症为慢性淋巴细胞白血病和套细胞淋巴瘤,84%的患者接受依鲁替尼单药治疗。
  • 43例(11.4%)发生严重感染,主要发生在依鲁替尼治疗第一年。
  • 严重感染患者中,侵袭性细菌感染23例(53.5%),侵袭性真菌感染16例(37.2%)。
  • 侵袭性真菌感染患者中62.5%缺乏经典临床危险因素(即中性粒细胞减少、淋巴细胞减少和接受糖皮质激素)。
  • 感染导致43例中6例(14%)死亡。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Ibrutinib is a Bruton tyrosine kinase inhibitor that is used for the treatment of lymphoid cancers, including chronic lymphocytic leukemia, Waldenström macroglobulinemia, and mantle cell lymphoma. Several case series have described opportunistic infections among ibrutinib recipients, but the full extent of these infections is unknown. We sought to determine the spectrum of serious infections associated with ibrutinib treatment. METHODS: We reviewed the electronic medical records of patients with lymphoid cancer at Memorial Sloan Kettering Cancer Center who received ibrutinib during a 5-year period from 1 January 2012 to 31 December 2016. Serious infections were identified by review of the relevant microbiology, clinical laboratory, and radiology data. Risk factors for infection were determined by means of univariate and multivariate analyses. RESULTS: We analyzed findings in 378 patients with lymphoid cancer who received ibrutinib. The most common underlying cancers were chronic lymphocytic leukemia and mantle cell lymphoma. 84% of patients received ibrutinib as monotherapy. Serious infection developed in 43 patients (11.4%), primarily during the first year of ibrutinib treatment. Invasive bacterial infections developed in 23 (53.5%) of these patients, and invasive fungal infections (IFIs) in 16 (37.2%) .The majority of patients with IFIs during ibrutinib therapy (62.5%) lacked classic clinical risk factors for fungal infection (ie, neutropenia, lymphopenia, and receipt of corticosteroids). Infection resulted in death in 6 of the 43 patients (14%). CONCLUSIONS: Patients with lymphoid cancer receiving ibrutinib treatment are at risk for serious infections, including IFIs.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Varughese T, Taur Y, Cohen N, et al. Serious Infections in Patients Receiving Ibrutinib for Treatment of Lymphoid Cancer. Clin Infect Dis. 2018. PMID: 29509845. doi:10.1093/cid/ciy175

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。